

MATERIALS TRANSFER AGREEMENT

Provider: EPA National Center for Computational Toxicology

Provider Contact (not signator):

Name: Katherine Coutros

Address: 109 TW Alexander Drive Durham, NC 27713

Phone: 919-541-2433

Email: coutros.katherine@epa.gov

Recipient: Alaska State Environmental Health Laboratory

Recipient Contact (not signator):

Name: Jackie Knue

Address: 5251 Dr. MLK Jr. Ave. Anchorage, AK 99507-1293

Phone: 907-375-8229

Email: Jacqueline.Knue@alaska.gov

1. Provider agrees to transfer to Recipient the following Research Material:

Perfluorobutanesulfonic acid, DTXSID5030030, 375-73-5;

Perfluorononanoic acid, DTXSID8031863, 375-95-1;

Perfluorooctanesulfonic acid, DTXSID3031864, 1763-23-1;

Perfluorooctanoic acid, DTXSID8031865, 335-67-1;

Perfluoroheptanoic acid, DTXSID1037303, 375-85-9; &

Perfluorohexanesulfonic acid, DTXSID7040150, 355-46-4.

2. This Research Material may not be used in human subjects. The Research Material will be used only for research purposes by Recipient's investigator in his/her laboratory, for the research project described below, under suitable containment conditions. This Research Material will not be used for screening, production or sale, for which a commercialization license may be required. Recipient agrees to comply with all Federal rules and regulations applicable to the Research Project and the handling of the Research Material.

EPA ONLY: If the data or material that are being transferred constitute human subjects research, please visit the following intranet site to determine if your project needs review and approval by the HSRRO: <http://intranet.ord.epa.gov/p2/hsr/human-subjects-review>

There is no Human Subjects material being used in this research

Research Plan reviewed and approval by HSRRO: Name:

Date:

Date:

3. The EPA Internal Review Entity (IRE) has determined that:

this research does not meet the Dual Use Research of Concern (DURC) definition and no additional review and oversight are required. The PI must report to the IRE any results or changes in the research such that one or more of the 7 categories of experimental effects may apply, or if the PI feels that the research may be DURC.

this research meets the DURC definition and requires additional oversight under the *USG Policy for Institutional Oversight of DURC*. Corresponding USG funding agency will be notified and a draft of the mitigation plan will be submitted within 90 days of this determination.

Mitigation Plan submitted to the funding agency on _____

Approved mitigation Plan on file

Please visit: <http://www.phe.gov/s3/dualuse/Pages/default.aspx>

4. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows (*insert description here or use an attachment page if necessary*):

Determine if current instrument (Shimadzu SIL-20AC HT HPLC & Ab-Sciex API5000) is adequate to perform EPA 537.1 PFAS analysis.

5. In all oral presentations or written publications concerning the Research Project, Recipient will acknowledge Provider's contribution of this Research Material unless requested otherwise. To the extent permitted by law, Recipient agrees to treat as confidential, any of Provider's written information about this Research Material that is stamped "CONFIDENTIAL" for a period of three (3) years from the date of its disclosure to recipient. The foregoing shall not apply to information that is or becomes publicly available or which is disclosed to Recipient without a confidentiality obligation. Any oral disclosures from Provider to Recipient which Provider wishes to be treated as confidential shall be identified as being Confidential at the time of the disclosure and by written notice delivered to Recipient within thirty (30) days after the date of the oral disclosure. Recipient may publish or otherwise publicly disclose the results of the Research Project, but if Provider has given Confidential information to Recipient, such public disclosure may be made only after Provider has had thirty (30) days to review the proposed disclosure to determine if it includes any Confidential information, to the extent such review period is permitted by law.

Date:

6. This Research Material represents a significant investment on the part of Provider and is considered proprietary to Provider. Recipient's investigator therefore agrees to retain control over this Research Material and further agrees not to transfer the Research Material to other people not under his/her direct supervision without advance written approval of Provider. Provider reserves the right to distribute the Research Material to others and to use it for its own purposes. When the Research Project is completed, the Research Material will be returned to the Provider or disposed, if directed by Provider.

7. This Research Material is provided as a service to the research community. It is being supplied to Recipient with no warranties, express or implied, including any warranty of merchantability or fitness for a particular purpose. Provider makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties.

8. Recipient shall retain title to any patent or other intellectual property rights in inventions made by its employees in the course of the Research Project. However, if said inventions contain any portion of the Research Material, are derived from the Research Material, or could not have been produced but for the use of the Research Material, Recipient agrees to contact the Provider to determine what ownership interests, if any, the Provider may have, and, where applicable, to negotiate in good faith the terms of a commercial license. Inventorship for a patent application or a commercialized product based on said inventions shall be determined according to United States patent law.

9. When Provider is the EPA: Recipient agrees not to claim, infer, or imply endorsement by the Government of the United States of America (hereinafter referred to as "Government") of the Research Project, the institution or personnel conducting the Research Project or any resulting product(s). Recipient agrees to hold the Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of Recipient's use for any purpose of the Research Material.

10. When Recipient is the EPA: Provider will not be liable to EPA for any claims or damages arising from EPA's use of the Research Material.

11. The Provider shall have the right to terminate this Agreement at any time if Recipient breaches any of the terms of this Agreement. Upon termination, Recipient shall return to the Provider all unused portions of the Research Materials.

12. Will EPA develop any products or services from information or materials provided by the Recipient?

Yes – go to item A

No – skip to #13 (next clause)

Date:

Item A: The EPA laboratory must coordinate on matters related to Quality Assurance with their QA Specialist.

If necessary, the Laboratory will develop/has developed a Quality Assurance Plan in coordination with the Quality Assurance Specialist.
 No QA requirements are needed.

13. All notices pertaining to or required by this Agreement shall be in writing and shall be signed by an authorized representative and shall be delivered by hand (including private courier mail service) or sent by certified mail, return receipt requested, with postage prepaid, addressed as follows:

Provider's Contact Information:

Katherine Coutros

Official's Name & Title

109 TW Alexander Drive, Durham NC 27713

Mailing Address

919-541-2433

Phone & Fax Number

coutros.katherine@epa.gov

Email address

Recipient's Contact Information:

Jackie Knue Chemist V

Official's Name & Title

5251 Dr. MLK Jr. Ave. Anchorage, AK 99507-1293

Mailing Address

907-375-8229 & 907-929-7335

Phone & Fax Number

Jacqueline.Knue@alaska.gov

Email address

With a copy to:

Date:

Kathleen Graham
FTTA Program Coordinator
Graham.Kathleen@epa.gov
(303) 312-6137
FTTA@epa.gov

14. Paragraphs 2, 8, 10 and 11 shall survive termination.
15. This Agreement shall be construed in accordance with law as applied by the Federal courts in the District of Columbia.
16. The undersigned Provider and Recipient expressly certify and affirm that the contents of any statements made herein are truthful and accurate.
17. This agreement shall enter into force as of the date of the last signature of the parties and shall remain in effect for one year from said date.